FOLH1 and prostate cancer: Receptor targeting radiotracers, such as [68 Ga]-Ga-DOTA-TATE, targeting somatostatin receptor 2 expression in neuroendocrine [6] and thymic endothelial tumours [7], [68 Ga]-Ga-PSMA (prostate-specific membrane antigen) [8] and [18F]F-PSMA [9], primarily targeting PSMA expression in prostate cancer, and quinoline-based [68 Ga]-labelled tracers that target fibroblast-activation-protein overexpressed in primary and metastatic tumours [10–12] have emerged as potent alternatives to [18F]FDG for cancer detection and monitoring.